Healtcare Liver Cancer Therapeutics Market | Page 2

at the San Diego School of Medicine and University of California found that long-term exposure to
triclosan, a common ingredient in detergents and soaps, causes liver fibrosis and cancer in
laboratory mice. However, triclosan has not been proven to cause liver cancer in human and it is
currently under scrutiny by the Food and Drug Administration (FDA) to determine whether it has
negative health impacts.
Moreover, increasing prevalence of liver cancer in various regions is expected to drive growth of
the market. For instance, according to cancer research organization of UK, around 5,736 new cases
of liver cancer were reported in UK in 2015. Furthermore, according to cancer organization, around
40,710 new cases of liver cancer was diagnosed in the U.S. during 2017, three of which will be
hepatocellular carcinoma (HCC).
Organic and inorganic strategies by market players such as merger, collaboration, acquisition, and
research and development for developing new therapies for liver cancer is expected to boost growth
of the market. For instance, in 2013, Roche and Inovio Pharmaceuticals, Inc. entered into license
agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA
immunotherapies targeting hepatitis B and prostate cancer. It has also been shown that liver cancer
risk increases substantially with the increase in Body Mass Index (BMI) of an individual. More than
half of the adult population in the U.S. is overweight, which is propelling demand for therapeutic
drugs of liver cancer, which in turn is creating opportunities for manufacturers.
Liver cancer therapeutics Market – Restrain
Stringent regulatory approvals to ensure the safety of drugs and cost of these drugs may hamper the
growth of the liver cancer therapeutics market during the forecast period. For instance, in March
2017, ArQule, Inc’s product- tivantinib did not clear phase 3 clinical trial for hepatocellular
carcinoma (HCC) in japan, as it did not meet its primary endpoint of progression free survival
(PFS)
Liver cancer therapeutics Market - Regional Analysis
Geographically, global liver cancer therapeutics market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold
dominant position over the forecast period, owing to increasing funding for research and
development activities by government. American Liver Foundation is an organization that promote
education, support and research for the prevention, treatment, and cure of liver disease and since
1979, this organization has provided more than US$ 26 million in research funding. Furthermore,
liver cancer is more common in economies of Sub-Saharan Africa and Southeast Asia as compared
to the U.S. According to GLOBOCAN, in 2012, around 83% (50% in China alone) of the estimated
782,000 new cancer cases were reported worldwide. Moreover, in Sub Saharan African countries,
the risk of developing cancer and death from the same is high, owing to the late stage diagnosis and
lack of treatment, which is driving growth of the liver cancer therapeutics market.
Liver cancer therapeutics Market – Competitor